Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2008 3
2009 2
2010 5
2011 6
2012 5
2013 8
2014 7
2015 11
2016 10
2017 14
2018 14
2019 15
2020 40
2021 53
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

176 results
Results by year
Filters applied: . Clear all
Page 1
Cholangiocarcinoma: Epidemiology and risk factors.
Khan SA, Tavolari S, Brandi G. Khan SA, et al. Among authors: brandi g. Liver Int. 2019 May;39 Suppl 1:19-31. doi: 10.1111/liv.14095. Epub 2019 Mar 24. Liver Int. 2019. PMID: 30851228 Review.
Recent advances of immunotherapy for biliary tract cancer.
Rizzo A, Ricci AD, Brandi G. Rizzo A, et al. Among authors: brandi g. Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33215952 Review.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Among authors: brandi g. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.
BAP1 in solid tumors.
Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F. Di Nunno V, et al. Among authors: brandi g. Future Oncol. 2019 Jun;15(18):2151-2162. doi: 10.2217/fon-2018-0915. Epub 2019 Jun 4. Future Oncol. 2019. PMID: 31159579 Review.
Asbestos and Intrahepatic Cholangiocarcinoma.
Brandi G, Tavolari S. Brandi G, et al. Cells. 2020 Feb 12;9(2):421. doi: 10.3390/cells9020421. Cells. 2020. PMID: 32059499 Free PMC article. Review.
In Reply.
Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S. Brandi G, et al. Oncologist. 2016 Dec;21(12):e5-e6. doi: 10.1634/theoncologist.2016-0286. Epub 2016 Nov 2. Oncologist. 2016. PMID: 27807301 Free PMC article.
Evolution of the Experimental Models of Cholangiocarcinoma.
Massa A, Varamo C, Vita F, Tavolari S, Peraldo-Neia C, Brandi G, Rizzo A, Cavalloni G, Aglietta M. Massa A, et al. Among authors: brandi g. Cancers (Basel). 2020 Aug 17;12(8):2308. doi: 10.3390/cancers12082308. Cancers (Basel). 2020. PMID: 32824407 Free PMC article. Review.
Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Rizzo A, et al. Among authors: brandi g. Expert Opin Investig Drugs. 2021 Apr;30(4):389-399. doi: 10.1080/13543784.2021.1854724. Epub 2020 Dec 6. Expert Opin Investig Drugs. 2021. PMID: 33218269 Review.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Zhu AX, et al. Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Lancet Oncol. 2015. PMID: 26095784 Clinical Trial.
176 results